Oakmont Investment Advisors Inc. Takes $2.10 Million Position in Medtronic PLC $MDT

Posted by Geri Gentry on Sep 5th, 2026

Oakmont Investment Advisors Inc. acquired a new stake in Medtronic PLC (NYSE:MDT – Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm acquired 26,858 shares of the medical technology company’s stock, valued at approximately $2,101,000. Medtronic comprises about 1.5% of Oakmont Investment Advisors Inc.’s investment portfolio, making the stock its 18th biggest position.

A number of other institutional investors also recently bought and sold shares of the stock. Anfield Capital Management LLC raised its holdings in shares of Medtronic by 410.7% in the fourth quarter. Anfield Capital Management LLC now owns 286 shares of the medical technology company’s stock worth $27,000 after buying an additional 230 shares during the last quarter. Monetary Solutions Ltd purchased a new stake in shares of Medtronic during the fourth quarter valued at $27,000. Acumen Wealth Advisors LLC purchased a new stake in shares of Medtronic during the fourth quarter valued at $29,000. IAG Wealth Partners LLC acquired a new position in shares of Medtronic in the 2nd quarter valued at $30,000. Finally, Imprint Wealth LLC acquired a new position in shares of Medtronic in the 3rd quarter valued at $31,000. 82.06% of the stock is currently owned by institutional investors and hedge funds.

Medtronic News Summary

Here are the key news stories impacting Medtronic this week:

Positive Sentiment: Medtronic said executives will present at the Wells Fargo Healthcare Conference on September 8 and other upcoming investor events. These appearances could provide additional updates on growth initiatives, product launches, and financial guidance. Medtronic executives to speak at upcoming investor conferences
Positive Sentiment: Royal Bank of Canada reaffirmed its Outperform rating, while Stifel Nicolaus, Robert W. Baird, TD Cowen, and BTIG Research maintained bullish assessments or projected meaningful price appreciation. The broad analyst support reinforces investor confidence in MDT’s outlook. Royal Bank of Canada reaffirms Outperform rating
Positive Sentiment: New real-world evidence from Medtronic’s PERSIST addendum study is supporting the company’s Inceptiv spinal cord stimulation system. Further clinical validation could improve adoption prospects and strengthen the pain-management franchise. Medtronic’s PERSIST study builds real-world evidence
Positive Sentiment: Medtronic’s latest reported quarter exceeded expectations, with earnings of $1.45 per share versus a $1.39 consensus estimate and revenue of $9.76 billion versus $9.55 billion expected. Revenue increased 13.7% year over year, providing a favorable fundamental backdrop.
Neutral Sentiment: Unusually large options trading indicates elevated investor interest in MDT, but the activity does not by itself establish whether traders expect further gains or a pullback. Medtronic target of unusually large options trading
Negative Sentiment: A MarketWatch strategy highlighted Medtronic as a healthcare stock that may be overcrowded, recommending a bearish options position because many investors have already bet on additional gains. This raises the risk of profit-taking or volatility despite the positive fundamental and analyst backdrop. Healthcare stocks may be too crowded to own

Insider Transactions at Medtronic

In other Medtronic news, EVP Harry Kiil sold 4,189 shares of the company’s stock in a transaction that occurred on Monday, June 8th. The stock was sold at an average price of $80.44, for a total value of $336,963.16. Following the sale, the executive vice president owned 37,227 shares in the company, valued at approximately $2,994,539.88. This represents a 10.11% decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.27% of the company’s stock.

Wall Street Analyst Weigh In

MDT has been the subject of a number of research reports. Bank of America lifted their price target on Medtronic from $95.00 to $110.00 and gave the stock a “buy” rating in a research report on Wednesday. Evercore set a $105.00 price objective on Medtronic in a report on Monday, July 6th. Jefferies Financial Group restated a “hold” rating and issued a $88.00 price objective on shares of Medtronic in a research note on Thursday, June 4th. Wells Fargo & Company lifted their target price on Medtronic from $102.00 to $104.00 and gave the stock an “overweight” rating in a report on Wednesday. Finally, Leerink Partners dropped their target price on Medtronic from $117.00 to $104.00 and set an “outperform” rating on the stock in a research report on Thursday, June 4th. Nineteen equities research analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to data from MarketBeat, Medtronic presently has a consensus rating of “Moderate Buy” and an average target price of $103.92.

View Our Latest Stock Analysis on Medtronic

Medtronic Price Performance

NYSE:MDT opened at $94.12 on Friday. The firm’s fifty day moving average is $86.78 and its two-hundred day moving average is $85.37. The firm has a market cap of $120.47 billion, a price-to-earnings ratio of 23.18, a PEG ratio of 2.18 and a beta of 0.56. The company has a debt-to-equity ratio of 0.52, a quick ratio of 1.62 and a current ratio of 2.13. Medtronic PLC has a one year low of $73.31 and a one year high of $106.33.

Medtronic (NYSE:MDT – Get Free Report) last released its quarterly earnings data on Tuesday, September 1st. The medical technology company reported $1.45 earnings per share for the quarter, beating analysts’ consensus estimates of $1.39 by $0.06. The business had revenue of $9.76 billion during the quarter, compared to analyst estimates of $9.55 billion. Medtronic had a return on equity of 14.89% and a net margin of 13.93%.The company’s revenue was up 13.7% on a year-over-year basis. During the same quarter last year, the business posted $1.26 EPS. Medtronic has set its Q2 2027 guidance at 1.320-1.340 EPS and its FY 2027 guidance at 5.940-6.000 EPS. Research analysts expect that Medtronic PLC will post 5.96 EPS for the current year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Friday, October 16th. Shareholders of record on Friday, September 25th will be issued a $0.72 dividend. The ex-dividend date of this dividend is Friday, September 25th. This represents a $2.88 dividend on an annualized basis and a yield of 3.1%. Medtronic’s payout ratio is presently 70.94%.

About Medtronic

(Free Report)

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).